A new study by Brigham and Women's Hospital (BWH) researchers has harnessed data and new analysis tools to address this question in four common diseases: rheumatoid arthritis; celiac disease; coronary artery disease and myocardial infarction (heart attack); and type 2 diabetes.
The study will be electronically published on March 25, 2012 in Nature Genetics.
The researchers developed a new statistical method built upon "polygenic risk score analysis" to estimate the heritable component of these diseases that is explained by common differences throughout the genome.
Their method takes advantage of data from previously published genome-wide association studies, or GWAS, an approach used to scan DNA samples for common genetic markers seen throughout the population—called SNPs (single nucleotide polymorphisms).
According to senior author Robert Plenge, MD, PhD, BWH director of Genetics and Genomics in the Division of Rheumatology, Immunology and Allergy, "We used GWAS data and a Bayesian statistical framework to demonstrate that a substantial amount of risk to these four common diseases is due to hundreds of loci that harbor common causal variants with small effect, as well as a smaller number of loci that harbor rare causal variants."
Using data on rheumatoid arthritis, they estimated that variation in hundreds of locations throughout the genome might explain 20 percent of rheumatoid arthritis risk, after excluding all of the known rheumatoid arthritis genetic risk factors.
They used computer simulations to demonstrate that the underlying genetic risk in rheumatoid arthritis is largely explained by many common alleles rather than rare mutations.
They observed similar results for celiac disease (43 percent), myocardial infarction (48 percent) and type 2 diabetes (49 percent).
"What is remarkable is that our statistical model was broadly applicable to several common diseases, not just rheumatoid arthritis," said Plenge, who is also an assistant professor at Harvard Medical School and an associate member of the Broad Institute of MIT and Harvard. "Our study provides a clear strategy for discovering additional risk alleles for these and likely many other common diseases."
According to the researchers, these methods can be applied to other genome-wide datasets (e.g., GWAS or whole genome sequencing) to estimate the degree to which there is a genetic component.
One exciting possibility is assessing the genetic basis of individual response to drugs.
"Our method may be particularly useful for diseases and related traits that cannot be easily studied in families," said Eli Stahl, PhD, lead study author, BWH research associate and member of the National Institutes of Health-funded Pharmacogenomic Research Network (PGRN). "For traits such as treatment efficacy or toxicity, we often assume there is a genetic basis to the clinical variability observed among patients. Now, we have the statistical tools to quantify the extent to which this is the case directly."
"Our study reinforces a common thread in the literature, that many subtle differences throughout the genome explain much of the differences in risk for individuals for all kinds of diseases—this has powerful implications for the genetic architecture of disease, for risk prediction and prognosis, as well as for basic biology and developing new drug targets," said co-senior author Soumya Raychaudhuri, MD, PhD, BWH Division of Immunology, Allergy and Rheumatology, assistant professor of medicine at Harvard Medical School.
This research was done in collaboration with colleagues from the University of California, Los Angeles; University Medical Center and University of Groningen, The Netherlands; Massachusetts General Hospital; The University of Pennsylvania; Karolinska Institutet at Karolinska University Hospital Solna, Stockholm, Sweden; The Feinstein Institute for Medical Research; University of Toronto, Mount Sinai Hospital and University Health Network; University of Manchester; and University Medical Center, Utrecht.
This research was supported by the National Institutes of Health; the Intramural Research Program of the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); the Pharmacogenomics Research Network (PGRN) and National Institute of General Medical Sciences (NIGMS); the Canadian Institutes for Health Research; Ontario Research Fund; and a Canada Research Chair.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. BWH is the home of the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), www.brighamandwomens.org/research, BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 900 physician-investigators and renowned biomedical scientists and faculty supported by more than $537 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information about BWH, please visit www.brighamandwomens.org.
Marjorie Montemayor-Quellenberg | EurekAlert!
Further reports about: > Division > GWAS > Genetics > Immunology > Medical Wellness > Pharmacogenomic > Rheumatology > celiac disease > computer simulation > genetic basis > health care > health services > myocardial infarction > rheumatoid arthritis > risk factor > single nucleotide polymorphism > type 2 diabetes
Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View
22.06.2018 | University of Sussex
New cellular pathway helps explain how inflammation leads to artery disease
22.06.2018 | Cedars-Sinai Medical Center
Russian researchers together with their French colleagues discovered that a genuine feature of superconductors -- quantum Abrikosov vortices of supercurrent -- can also exist in an ordinary nonsuperconducting metal put into contact with a superconductor. The observation of these vortices provides direct evidence of induced quantum coherence. The pioneering experimental observation was supported by a first-ever numerical model that describes the induced vortices in finer detail.
These fundamental results, published in the journal Nature Communications, enable a better understanding and description of the processes occurring at the...
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
25.06.2018 | Physics and Astronomy
25.06.2018 | Earth Sciences
25.06.2018 | Power and Electrical Engineering